Strides Pharma soars on securing EIR from USFDA for manufacturing facility in Bengaluru
Strides Pharma Science is currently trading at Rs. 991.05, up by 34.05 points or 3.56% from its previous closing of Rs. 957.00 on the BSE.
The scrip opened at Rs. 989.90 and has touched a high and low of Rs. 1055.90 and Rs. 970.05 respectively. So far 376715 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1231.45 on 12-May-2026 and a 52 week low of Rs. 769.60 on 29-Jan-2026.
Last one week high and low of the scrip stood at Rs. 1,055.90 and Rs. 931.25 respectively. The current market cap of the company is Rs. 9051.82 crore.
The promoters holding in the company stood at 27.91%, while Institutions and Non-Institutions held 43.81% and 28.28% respectively.
Strides Pharma Science has secured Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its flagship manufacturing facility in Bengaluru, indicating the successful closure of the inspection conducted at the facility. Earlier, the USFDA had conducted a current Good Manufacturing Practices (cGMP) inspection of the facility from May 12 to May 20, 2026. The inspection concluded with the issuance of a Form 483 that contained five observations.
The company submitted a comprehensive response addressing all observations within the stipulated timeline. Based on the company's response and the corrective and preventive actions implemented, the USFDA has classified the inspection outcome as Voluntary Action Indicated (VAI) and has issued the EIR.
The facility is the company's flagship manufacturing site and serves regulated and other international markets. The facility manufactures a broad portfolio of pharmaceutical dosage forms, including tablets, capsules and oral liquids, supporting both existing commercial products and future growth opportunities. The successful closure of the inspection further strengthens the company's regulatory track record and reinforces its commitment to supplying high-quality pharmaceutical products to patients across global markets.
